Physician profile
Glenn Rosett
NPI 1871520049
$8,546.82
in general payments reported to CMS, 2019-2025
16 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,269 · 2020: $1,109 · 2021: $596 · 2022: $940 · 2023: $1,188 · 2024: $971 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,633.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,682.05 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $1,679.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $1,194.36 | 2019-2025 | |
| Abbott Laboratories | $999.72 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.98 | 2019-2022 | |
| Amgen INC. | $462.91 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $357.17 | 2019-2022 | |
| Pfizer INC. | $354.42 | 2019-2020 | |
| Amarin Pharma, INC. | $252.65 | 2019-2020 | |
| Glaxosmithkline, LLC. | $223.82 | 2019-2024 | Arexvy |
| Novo Nordisk INC | $181.63 | 2019-2022 | |
| Gilead Sciences, INC. | $124.77 | 2019 | |
| Jazz Pharmaceuticals INC. | $124.77 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2024 | |
| Inspire Medical Systems, INC. | $112.78 | 2023 | Inspire |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $85.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Rosett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.